Loading
A phase 3 trial testing Cevostamab in multiple myeloma, now recruiting.
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma is a phase 3 interventional study registered as NCT07555938, led by Hoffmann-La Roche, and recruiting on the registry. Official title: A Phase III, Randomised, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Patients With Multiple Myeloma Who Have Received One to Three Prior Lines of Therapy. Planned enrolment is 380 participants (estimated). The study started in 2026-06-23 and primary completion is expected in 2028-10-31. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Cevostamab, Relapsed or refractory multiple myeloma, Roche / Genentech, Multiple myeloma.
Shares Cevostamab, Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Cevostamab, Roche / Genentech, Multiple myeloma.
Shares Cevostamab, Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/